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Transfection of brain capillary 
endothelial cells in primary culture with defined 
blood–brain barrier properties
Annette Burkhart1, Louiza Bohn Thomsen1, Maj Schneider Thomsen1, Jacek Lichota1, Csilla Fazakas2, 
István Krizbai2 and Torben Moos1*
Abstract 
Background: Primary brain capillary endothelial cells (BCECs) are a promising tool to study the blood–brain barrier 
(BBB) in vitro, as they maintain many important characteristics of the BBB in vivo, especially when co-cultured with 
pericytes and/or astrocytes. A novel strategy for drug delivery to the brain is to transform BCECs into protein facto-
ries by genetic modifications leading to secretion of otherwise BBB impermeable proteins into the central nervous 
system. However, a huge challenge underlying this strategy is to enable transfection of non-mitotic BCECs, taking a 
non-viral approach. We therefore aimed to study transfection in primary, non-mitotic BCECs cultured with defined BBB 
properties without disrupting the cells’ integrity.
Methods: Primary cultures of BCECs, pericytes and astrocytes were generated from rat brains and used in three dif-
ferent in vitro BBB experimental arrangements, which were characterised based on a their expression of tight junction 
proteins and other BBB specific proteins, high trans-endothelial electrical resistance (TEER), and low passive perme-
ability to radiolabeled mannitol. Recombinant gene expression and protein synthesis were examined in primary 
BCECs. The BCECs were transfected using a commercially available transfection agent Turbofect™ to express the red 
fluorescent protein HcRed1-C1. The BCECs were transfected at different time points to monitor transfection in relation 
to mitotic or non-mitotic cells, as indicated by fluorescence-activated cell sorting analysis after 5-and 6-carboxylfluo-
rescein diacetate succinidyl ester incorporation.
Results: The cell cultures exhibited important BBB characteristics judged from their expression of BBB specific pro-
teins, high TEER values, and low passive permeability. Among the three in vitro BBB models, co-culturing with BCECs 
and astrocytes was well suited for the transfection studies. Transfection was independent of cell division and with 
equal efficacy between the mitotic and non-mitotic BCECs. Importantly, transfection of BCECs exhibiting BBB charac-
teristics did not alter the integrity of the BCECs cell layer.
Conclusions: The data clearly indicate that non-viral gene therapy of BCECs is possible in primary culture conditions 
with an intact BBB.
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publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The blood-brain barrier (BBB) denotes the interface 
between the circulation and the central nervous system 
(CNS). It is formed by non-fenestrated brain capillary 
endothelial cells (BCECs) that control the flux of sub-
stances into the CNS. Other non-neuronal cells of the 
CNS, mainly astrocytes and pericytes, form the neu-
rovascular unit together with BCECs and support the 
function of the BBB to restrict both paracellular and 
transcellular transport pathways to the CNS [1–4]. The 
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robust expression of tight and adherence junction pro-
teins between BCECs. These junctions lead to the forma-
tion of major gradients for inorganic and organic solutes 
between the brain and the blood plasma. This accounts 
for the existence of high transcellular endothelial electric 
resistance (TEER) across BCECs [5]. Transcellular trans-
port across BCECs is diminutive with respect to hydro-
philic molecules [1–4]. Furthermore, the expression of 
several efflux transporter proteins like the ATP-binding 
cassette transporters prevents exogenous substances that 
are lipophilic in nature to pass through the BCECs [6–8].
In order to enable high-throughput screening for per-
meability of putative CNS acting drugs, much effort has 
been devoted to designing reliable in vitro models of the 
BBB. Primary BCECs have been isolated from a variety 
of animal sources [2, 3, 9–15], which has also resulted 
in establishment of immortalised cells lines. These have 
been widely used to study the BBB, but unfortunately, 
they seem to lose many important BBB characteristics 
in culture [16–18]. The biggest challenge is to main-
tain the in  vivo characteristics of BCECs with respect 
to high TEER and low passive permeability when cul-
tured in vitro, and primary isolated BCECs are the most 
promising tool to study the BBB in vitro [4, 16–19]. An 
additional way to mimic the microenvironment is by cul-
turing BCECs together with astrocytes and pericytes as 
co- or triple cell cultures. These culturing conditions sig-
nificantly up-regulate the expression of important tight 
junction proteins like zona occludens 1 (ZO1) and clau-
din-5, which lead to intended higher TEER values and 
low passive permeability [2, 3, 15, 19].
Gene therapy to BCECs, choroid plexus epithelium 
and ependymal have been proposed as a promising 
drug delivery strategy for the delivery of otherwise non-
permeable proteins into the CNS [20–22]. The strategy 
involves genetically modifying the BCECs to express and 
secrete a protein of interest into the CNS [23, 24]. Pre-
vious studies using this strategy have primarily studied 
gene therapy in mitotic immortalized BCECs without any 
seemingly BBB properties, using a gene carrier of non-
viral origin [23–26]. Non-viral gene carriers are generally 
believed to be highly dependent on cell division for deliv-
ery of genetic material to the nucleus [27–29]. However, 
in vivo the BCECs are non-mitotic [30], which denotes a 
major hazard for gene transfection.
A remaining challenge in the future perspectives of 
genetically modifying BCECs into protein factories  is 
therefore to transfect non-mitotic primary BCECs with 
defined BBB properties. It would be necessary to inves-
tigate whether non-mitotic BCECs are receptive for 
delivery of genetic material by a non-viral carrier, and 
subsequently process the encoded protein, without com-
promising the barrier properties of the BCECs. This was 
therefore, the main aim of the present study using a plas-
mid encoding the red fluorescent protein HcRed1-C1.
An in  vitro BBB model using primary cells isolated 
from rat brains was established. Three different models 
were established and characterised with respect to TEER 
values, permeability and expression of cell-specific mark-
ers. A co-culture model of BCECs and astrocytes was the 
most stable model and was subsequently used to deter-
mine that non-mitotic BCECs with defined barrier prop-
erties were receptive for delivery of genetic material 
by a non-viral carrier, and subsequently processed the 
encoded protein, without compromising barrier proper-
ties of the BCECs.
Methods
Materials
Poly(vinylpurrolidone)-iodine complex (Cat. No. PVP1), 
Percoll (Cat. No. P1644), collagen type IV (Cat. No. 
C5533), fibronectin (Cat. No. F1141), poly-l-lysine (Cat. 
No. P6282), heparin (Cat. No. H3149), puromycin (Cat. 
No. P8833), hydrocortisone (Cat. No. H4001), CTP-
cAMP (Cat. No. C3912), 4-(3-Butoxy-4-methoxyben-
zyl)imidazolidin-2-one (RO-201724) (Cat. No. B8279), 
competent CG5 Escherichia coli (Cat. No. G3169), 4′, 
6-Diamidino-2-phenylindole dihydrochloride (DAPI) 
(Cat. No. D9542) and mouse anti-alpha-smooth mus-
cle actin (α-SMA) (Cat. No. A5228) were obtained 
from Sigma-Aldrich (Brondby, Denmark, DK). DNase 
I (Cat. No. 10104159001), Collagenase/Dispase (Cat. 
No. 109113), insulin transferrin sodium selenite (Cat. 
No. 11074547001) and basic fibroblast growth factor 
(bFGF) (Cat. No. 1363697) were from Roche (Hvidovre, 
Denmark, DK). Rabbit anti-ZO1 (Cat. No. 61-7300), 
Alexa Fluor 488-conjugated goat anti-rabbit IgG (Cat. 
No. A11034), Alexa Fluor 594-conjugated goat anti-
mouse IgG (Cat. No. A11032), collagenase II (Cat. No. 
17101105), Dulbecco’s Modified Eagle Medium consist-
ing of nutrient Mixture F-12 (DMEM/F-12) (Cat. No. 
31331), DMEM (Cat. No. 21885) and fetal calf serum 
(Cat. No. 10270) were from Life Technology (Naerum, 
Denmark, DK). Bovine serum albumin (BSA) (Cat. No. 
EQBAH62) was from Europa Bioproducts (Cambridge, 
United Kingdom, UK). Plasma derived bovine serum 
(Cat. No. 60-00-810) was from First Link (Wolverhamp-
ton, United Kingdom, UK). Gentamicin sulphate (Cat. 
No. 17-518Z) was from Lonza Copenhagen (Vallensbaek 
Strand, Denmark, DK). Fluorescence mounting media 
(Cat. No S3023) and rabbit anti-glial fibrillary acidic 
protein (GFAP) (Cat. No. Z0334) were from DAKO 
(Glostrup, Denmark, DK). 3H D-Mannitol (Cat. No 
NET101250UC) and Ultima Gold™ liquid scintillation 
cocktail (Cat. No. 6013326) were from Pelkin Elmer (Sko-
vlunde, Denmark, DK). Turbofect™ (Cat. No. R0531), and 
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reagents for qPCR were from Thermo Scientific, except 
primers synthesised by TAG Copenhagen (Frederiks-
berg, Denmark, DK). Clonetech pHcRed1-C1 plasmid 
(Cat. No 632415) and Promokine Cell proliferation kit I 
(CFDA SE) were from BioNordika Denmark A/S (Her-
lev, Denmark, DK). Macherey–Nagel NucleoBond®Xtra 
Midi EF plasmid DNA purification kit (Cat. No. 740410) 
was from AH diagnostics (Aarhus, Denmark, DK). Hang-
ing cell culture inserts (Cat. No. Pirp 15R48) were from 
Merck Milipore (Hellerup, Denmark, DK).
Cell culture
Primary cultures of BCECs were prepared from 2 to 
3 weeks old Sprague–Dawley rats using slight modifica-
tions of the protocol of Nakagawa et al. [19]. The proce-
dures dealing with the handling of rats as described in 
this study were approved by the Danish National Coun-
cil of Animal Welfare. One isolation required nine to 
twelve rats, which resulted in approximately 5–8 million 
endothelial cells. The rats were anesthetised by subcuta-
neous injection of 0.5 ml/10 g body weight of Hypnorm/
Dormicum (Fentanyl/Fluanisone mixed with Midazolam 
and sterile water in ratio of 1:1:2). Heads were rinsed with 
70% ethanol and 10% poly(vinylpurrolidone)-iodine com-
plex before decapitation. Under sterile conditions, brains 
were gently dissected, and forebrains collected in ice-cold 
PBS. Care was taken to remove meninges and any visible 
white matter, before the cerebral cortices were cut into 
small pieces using sterile razor blades. The tissue was 
digested in collagenase II and DNase I in DMEM-F12 at 
37°C for 75 min until terminated by diluting in DMEM-
F12 followed by centrifugation at 1,000G for 8 min. The 
pellet was resuspended in 20% BSA in DMEM-F12 and 
centrifuged at 1,000G for 20  min. Microvessels pre-
sent in the pellet were further digested in collagenase/
dispase and DNase I in DMEM/F12 at 37°C for 50 min. 
The digested microvessel fragments were separated on a 
continuous 33% Percoll gradient. The microvessel frag-
ments were seeded on collagen type IV and fibronectin 
coated 35 mm plastic dishes. Primary cultures of BCECs 
were maintained in DMEM/F12 supplemented with 10% 
plasma derived bovine serum, bFGF, heparin, insulin–
transferrin–sodium selenite and gentamicin sulphate and 
cultured in an incubator with 5% CO2/95% air at 37°C. 
Puromycin was added to the culture media (4 µg/ml) for 
the first 2 days to obtain a pure culture of BCECs, which 
in contrast to pericytes are able to thrive due to their high 
expression of efflux pumps that scavenges the intracellu-
lar toxicity generated by puromycin [31].
Primary cultures of pericytes were obtained by pro-
longed culture of isolated microvessel fragments. These 
microvessel fragments contain both BCECs and peri-
cytes; however, by culturing the microvessel fragments 
on uncoated dishes in DMEM supplemented with 10% 
fetal calf serum and gentamicin sulphate for about 
10 days, pericyte survival and proliferation was favoured 
and BCECs died. The pericytes were frozen in DMEM 
supplemented with 30% FCS and 7.5% DMSO for later 
use. They were thawed and cultured for 3  days before 
being used in the experiments.
Primary cultures of astrocytes were obtained from neo-
natal Sprague–Dawley rat pups. The pups were rapidly 
decapitated, their brains dissected and pieces of the cer-
ebral cortex mechanically dissociated through a 40  µm 
nylon strainer in DMEM supplemented with 10% fetal 
calf serum and gentamicin sulphate. Dissociated cells 
were seeded in poly-l-lysine coated culture flasks for 
approximately 2  weeks until they reached confluence. 
Thereafter, the cells were either frozen or seeded directly 
in poly-l-lysine coated 12 well culture plates for about 
2  weeks before being used for co-culture experiments 
with BCECs and pericytes. It was consistently found that 
the freezing step could be performed without reduction 
in the cells capacity to influence their inductive effects on 
the barrier formation of BCECs.
Construction of in vitro BBB models
Three in  vitro BBB models were prepared: monocul-
tures of BCECs, non-contact co-cultures of BCECs and 
astrocytes, and triple cultures consisting of BCECs, peri-
cytes and astrocytes. Three days after isolation, BCECs 
reached about 80% confluence and were passaged onto 
collagen type IV- and fibronectin-coated 12 well polyeth-
ylene terephthalate, 1.0  µm hanging cell culture inserts 
at a cell density of 1 × 105 cells/cm2. The cells were left 
to adhere to the inserts overnight. To construct non-
contact cultures, BCECs were seeded on the upper side 
of the inserts, before the inserts were placed in 12 well 
culture plates containing a confluent layer of astrocytes. 
To construct triple cultures, pericytes were seeded on 
the bottom side of the coated inserts at a cell density of 
1.5 ×  104 cells/cm2 and left to adhere for 4–5 h, before 
BCECs were seeded on the upper side. The inserts were 
placed in 12 well culture plates containing confluent layer 
of astrocytes grown at the bottom of the wells. To further 
induce BBB characteristics, BCECs were treated with 
hydrocortisone, cAMP and RO-201724 in concentrations 
of 550 nM, 250 µM and 17.5 µM respectively [4, 32].
Immunocytochemistry
Cells were washed in 0.1 M PBS, pH 7.4, fixed with abso-
lute ethanol/acetic acid in a ratio of 95:5% for 10 min at 
−20°C. They were washed 3 × 5 min in 0.1 M PBS fol-
lowed by blocking non-specific binding of primary 
antibodies using 3% BSA in PBS for 30 min at room tem-
perature. BCECs were incubated with antibodies raised 
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against ZO1 (endothelial cells), α-SMA (pericytes), or 
GFAP (astrocytes). These primary antibodies were used 
at a dilution of 1:200 in 1% BSA/0.1 M PBS, pH 7.4 and 
incubated overnight at 4°C. Alexa Fluor 488-conjugated 
goat anti-rabbit IgG and Alexa Fluor 594-conjugated 
goat anti-mouse IgG secondary antibodies were used at 
a dilution of 1:200 in 1% BSA in 0.1 M PBS, pH 7.4 and 
incubated for 30 min at room temperature. Nuclei were 
stained with DAPI. The cells were mounted on glass 
slides with fluorescent mounting medium, and examined 
in a fluorescence microscope (Axiovert 2000, Carl-Zeiss, 
Germany). Captured images were corrected for bright-
ness and contrast using Adobe Photoshop C2 software.
Trans‑endothelial electrical resistance (TEER) 
measurements
TEER was measured to evaluate the integrity of the 
in vitro BBB models. TEER, which in culture conditions 
reflects the flux of mainly sodium ions through an intact 
cell layer, was measured using a Millicell ERS-2 epithe-
lial Volt-Ohm meter and STX01 Chopstick Electrodes 
(Millipore, Hellerup Denmark, DK). The TEER values 
of coated but cell-free inserts were subtracted from the 
measured TEER values, and the difference was multi-
plied with the size of the insert (1.12  cm2). Measured 
TEER values are given as Ω cm2. Data were analysed with 
GraphPad Prism 5.0 software (GraphPad Software, Inc., 
CA, USA) using two-way ANOVA with Bonferroni post 
hoc test.
Passive permeability across the BCECs
Functional integrity of the BBB models was determined 
using radiolabeled mannitol [33]. 3H-D-Mannitol (spe-
cific activity 14.2 Ci/mmol) was added to the upper 
chamber in concentration of 1  µCi/ml and incubated 
with cells for 2 h at 37°C on a rocking table. Donor sam-
ples (100  µl) were taken from the upper chamber at 0 
and 120  min, and receiver samples (100  µl) were taken 
from the lower chamber at 0, 15, 30, 60 and 120  min 
and replaced with 100  µl fresh media. Samples were 
added with Ultima Gold Scintillations fluid and counted 
in a LKB Wallac Rackbeta Liquid Scintillation Counter, 
Model 1209. The permeability studies were performed on 
eighteen inserts on the second day of high TEER (day 2), 
and the permeability data were plotted as the total num-
ber of millimoles transported against time in each well. 
The flux at steady state across the inserts was calculated 
as the slope of the straight line at steady state divided by 
the area of the insert. The apparent permeability (Papp) 
was calculated by dividing the observed flux at steady 
state (J) with the initial concentration in the donor com-
partment (Cdonor). The Papp values were plotted against 
TEER for the individual inserts.
RT‑qPCR
Gene expression analyses were performed on BCECs 
cultured in mono-, co- and triple culture conditions. For 
each RNA sample, RNA was isolated from 20 individual 
inserts and pooled into four samples each containing five 
inserts. This procedure was further repeated twice to 
yield cells from two different isolations, which resulted in 
eight RNA samples (n = 8) for each of the three different 
cell culture conditions. RNA was extracted from BCECs 
using the GeneJET RNA Purification Kit and treated with 
DNase I enzyme according to the manufacture’s protocol. 
100 ng of each DNA-free RNA sample was used as a tem-
plate for RT-qPCR. cDNA synthesis was carried out with 
the RevertAid Premium First Strand cDNA Synthesis Kit. 
To assess the expression profile of BCECs specific pro-
teins, quantitative RT-PCR was performed with primers 
specific for claudin-5, occludin, platelet/endothelial cell 
adhesion molecule 1 (PECAM-1), Transferrin receptor 1 
(CD-71), ATP-binding cassette, sub-family G, member 2 
(ABCG2), also known as breast cancer resistance protein 
(BCRP) and ATP-binding cassette, sub-family B, member 
1 (ABCB1), also known as p-glycoprotein (PgP) (Table 1). 
Beta-actin was used as housekeeping control gene for 
normalisation purpose. 2.5  ng cDNA and 10  pmol of 
each primer were used for each PCR reaction together 
with the Maxima™ SYBR Green qPCR Master Mix. Each 
sample was performed in triplicates, and not reverse-
transcribed RNA and water served as negative controls. 
Quantitative RT-PCR was performed using the Strata-
gene Mx 3000P™ QPCR System (Agilent Technologies, 
Horsholm, Denmark, DK). The PCR conditions were 
95°C for 10 min, followed by 40 cycles of: 95°C for 30 s, 
60°C for 30  s and 72°C for 30  s. The relative quantities 
of DNA in the analysed samples were calculated by the 
Pfaffl method [34]. Data were analysed by the GraphPad 
Prism 5.0 software using one-way ANOVA with Tukey’s 
multiple comparisons post hoc test.
Measurement of endothelial cell proliferation
BCECs cell division was measured using the PromoKine 
cell proliferation kit I (CFDA SE), according to manu-
factures protocol. CFDA SE is also known as CFSE. 
The fluorescent tracer (495/519) passively diffuses into 
cells where it binds covalently to intracellular proteins. 
CFDA SE becomes fluorescent after hydrolysis by intra-
cellular esterases, which results in long term labelling 
of the cell. This label is inherited through successive cell 
divisions, and with every cell division, each of the two 
daughter cells receives approximately half of the label 
[35]. To analyse the cell division pattern of BCECs, iso-
lated microvessels were seeded directly onto collagen 
type IV- and fibronectin-coated inserts. The cells were 
maintained in 4 µg/ml puromycin media for 2 days. One 
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day after isolation (day −2) the cells were incubated with 
pre-warmed 1 µM CFDA SE in PBS for 15 min to label 
the cells. Then labelling solution was replaced with pre-
warmed medium for 30 min to ensure sufficient hydroly-
sis of CFDA SE. Labelled cells were cultured for 0–5 days 
(day −2 to day 3) to allow for cell division. Every 24  h, 
labelled cells were terminated by detaching the cells of 
four individual inserts with fixation in 4% paraformalde-
hyde. At day 0 the cells appeared confluent, growing as 
a solid monolayer without cells growing on top of each 
other. They were therefore co-cultured with astrocytes 
and BBB characteristics were induced by supplementing 
the media with hydrocortisone, cAMP and RO. TEER 
was measured daily. Cell divisions were tracked using 
fluorescence-activated cell sorting (FACS) Canto™ flow 
cytometer (BD bioscience, Albertslund, Denmark, DK). 
Prior to the flow cytometic analysis the instrument acqui-
sition parameters were calibrated using FACS 7 colour 
beads (BD bioscience). The cells were gated using for-
ward and side scatters to eliminate cell debris. Unlabelled 
BCECs were negative control. The results were analysed 
using the FlowJo V10 software (TreeStar, Ashland, OR, 
USA).
In vitro transfection of BCECs with HcRed1‑C1
A plasmid encoding the protein HcRed1-C1 [23] was 
propagated into competent CG5 E-coli strain by heat 
shock and purified with ion exchange chromatography 
using the NucleoBond®Xtra Midi EF plasmid DNA puri-
fication kit according to the manufacture’s protocol. A 
commercially available transfection reagent Turbofect™ 
was used for transfection. For the transfection studies, we 
took a novel culturing approach and seeded the isolated 
microvessels directly on collagen type IV- and fibronec-
tin-coated inserts to ease their handling at the time point 
when they were transferred to wells with astrocytes 
grown in the lower chamber. The endothelial cell prepa-
ration was maintained in 4  µg/ml puromycin media for 
2  days. Transfection was performed at different time 
points after isolation to obtain two different experimental 
conditions: non-confluent cells (T−1), and confluent cells 
with defined barrier properties (TEER >130 Ω cm2) [36] 
(T1). Cells added with transfectants at time point T1 were 
then transferred to grow in co-culture with astrocytes 
and further supplemented with hydrocortisone, cAMP 
and RO to induce barrier properties. Cells grown at T−1 
culture conditions were cultured without astrocytes, 
hydrocortisone, cAMP and RO.
For each insert, 1 μg plasmid was mixed with 100 μl 
medium without serum and 2 μl Turbofect™. The solu-
tion was incubated at room temperature for 15–20 min 
for complexes to form. The Turbofect™ solution (102 μl) 
was added to the luminal compartment in droplets 
that were dispersed throughout the wells, and the cells 
were cultured for 48  h in an incubator at 37°C with 5% 
CO2/95% air. TEER was measured daily to access the 
effects of transfection on the integrity of the cultures. 
Non-transfected cells served as control for TEER values. 
TEER data was analysed in the GraphPad Prism 5.0 soft-
ware using 2-way ANOVA with Bonferroni post hoc test.
After transfection cells were fixed in 4% paraformalde-
hyde for 10  min at room temperature and stained with 
DAPI. Some inserts were, additionally, stained for ZO1, 
as described above. The inserts were removed from their 
plastic supports with razor blades and mounted on glass 
slides using fluorescent mounting medium. The HcRed1-
C1 protein encoded by the HcRed1-C1 plasmid excites 
fluorescence excitation and emission maxima at 588 nm 
and 618 nm.
The transfection efficiency was analysed using RT-qPCR 
with primers specific for HcRed1-C1 (Table  1). Primers 
specific for claudin-5 were used to assess the origin of the 
transfected cells. Beta-actin was used as normalisation 
control. Non-transfected cells, not-reverse transcribed 
RNA and water served as negative controls. For each RNA 
sample, RNA was collected from four individual inserts. 
This was repeated twice to obtain cells from two different 
isolations; which resulted in sample values of six or eight 
Table 1 Primer sequences used for RT-qPCR analysis
Primer Reference sequence Forward primer Reverse primer
Claudin-5 NM_031701.2 CTACAGGCTCTTGTGAGGACTTGAC AGTAGGAACTGTTAGCGGCAGTTTG
Occludin NM_031329.2 CTGACTATGCGGAAAGAGTCGACAG AGAGGAATCTCCTGGGCTACTTCAG
PECAM-1 NM_031591.1 ATTCTATAAGGACGATGCGCTGGTG GCTGTTCAGTATCACGGTGCATTTG
TfR 1 NM_022712.1 TGGATCAAGCCAGATCAGCATTCTC TTTCTTCCTCATCTGCAGCCAGTTT
ABCG2 NM_181381.2 GAGTTAGGCCTGGACAAAGTAGCAG AAGAGGATGGAAGGGTCAGTGATGA
ABCB1 NM_012623.2 AATCAACAGTACACAGACCGTCAGC CCAAAGTGAAACCTGGATGTAGGCA
HcRed1-C1 pHcRed1-C1 (613-1377) ATGTACATGGAGGGCACCGTGAA GTCACGTGGATTCTCATGCTCTGG
β-actin NM_031144.3 CCTCTGAACCCTAAGGCCAACCGTGAA AGTGGTACGACCAGAGGCATACAGGG
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RNA samples for all conditions [T−1, T1 and non-trans-
fected cells (TCRTL)]. Data were analysed by the GraphPad 
Prism 5.0 software using a 1-way ANOVA with Tukey’s 
multiple comparisons post hoc test.
The transfection efficiency was further analysed using 
Flow cytometry. At the end of transfection, cells were 
washed in PBS, detached from the insert and fixed in 
4% paraformaldehyde. Cells expressing red fluorescence 
protein HcRed1-C1 were counted using the MoFlo® 
Astrios™ Flow cytometer system (Beckman Coulter, 
Copenhagen, Denmark, DK). Prior to the flow cytometric 
analysis the instrument parameters were calibrated using 
SPHERO™ ultra rainbow fluorescent particles (3  μm) 
(Spherotech, Lake Forrest, IL, USA). Cells were gated 
using forward and side scatters to eliminate cell debris. 
HcRed1-C1 positive cells were gated based on auto fluo-
rescence from unlabelled BCECs to ensure less than 1% 
false positive events occurred. The results were analysed 
using FlowJo V10 software.
Results
Establishment of BBB in primary culture
Three cell types were used to construct the three differ-
ent types of in vitro BBB models (Fig. 1a). Based on their 
respective expression of the cell specific markers ZO1, 
α-SMA and GFAP, the three isolated cell types were iden-
tified as BCECs, pericytes and astrocytes, respectively 
(Fig. 1b). Evaluating the integrity of the BCECs in these 
in  vitro models, the TEER measurements increased in 
all cultures in consequence to stimulation with hydro-
cortisone, cAMP and RO-201724. On day 2, the mono-, 
co- and triple culture models reached their maximal 
TEER values of 128 ± 9, 299 ± 17 and 331 ± 28 Ω cm2, 
respectively (Fig. 1c). TEER values of co- and triple cul-
tures were significantly higher than in monocultures, 
indicating the importance of co-culturing the BCECs 
with astrocytes and pericytes. The TEER values of triple 
culture were generally higher than that of the co-cultures 
albeit this difference was not statistically significant. A 
large variability was seen in the TEER values obtained 
with the triple culture (SEM  ±  28) compared to the 
mono- (SEM  ±  9) and co-culture (SEM  ±  17) models. 
Both co- and triple cultures maintained TEER above 
150 Ω cm2 until day 4, while monocultures failed to even 
reach 130 Ω  cm2 at any experimental day. TEER meas-
urements were not conducted beyond day 4, since TEER 
values decreased below 130 Ω cm2, at which stage in vitro 
BBB models using rat endothelial cells get insufficiently 
tight [36]. Evaluating the permeability of the endothelial 
monolayer to mannitol demonstrated that TEER values 
around 150 Ω cm2 and upwards clearly resulted in lower 
permeability to mannitol, which was did not decrease 
further, with higher TEER values. This is therefore in 
agreement with the observations reported by Gaillard 
and de Boer [36], and indicates that TEER values around 
130–150 Ω cm2 is sufficient to obtain a low permeability 
(Fig. 1d).
The in vitro models were also examined for expression 
of genes signifying BCECs. TEER was measured prior to 
RNA extraction and was 73 ± 14 Ω cm2 for monoculture, 
229 ± 34 Ω cm2 for co-culture and 243 ± 26 Ω cm2 for 
triple culture. BCECs grown in triple culture had a sig-
nificantly higher expression of claudin-5 and PECAM-1 
compared to the monoculture. Furthermore, ABCG2 
was statistically higher expressed in the triple cultures 
compared to both mono- and co- cultures. This expres-
sion correlates well with increasing TEER in the different 
culture models (Fig. 2). By contrast occludin, transferrin 
receptor 1 and ABCB1 did not show any statistic differ-
ence between groups.
Cell division among BCECs related to the stage of BBB 
maturity
Since no significant difference was found in TEER 
between co- and triple cultures, the co-culture was 
decided sufficient for further analyses concerning cell 
division and transfection studies. In order to establish a 
model in which different stages of barrier maturity could 
be analysed, the setup was slightly modified, and for this 
the co-culture model was most suitable. The BCECs 
were seeded directly onto the inserts on the day of iso-
lation (−3) (Fig. 3), visualised by phase contrast micros-
copy, and confluent by day 0. From day 0 the previous 
described setup (Fig. 1a) was followed by BBB induction 
and co-culturing with astrocytes at day 0. BBB proper-
ties were present from day 1 to 3 with TEER values well 
above 130 Ω cm2.
The different stages of barrier maturity were defined 
according to cell confluence and it was, therefore, impor-
tant to investigate whether BCECs continued their divi-
sion despite reaching confluence. Newly isolated BCECs 
were left to adhere to the insert for 24 h by which 1 µM 
CFDA SE was added to the BCECs on day −2. Every 
day from day −2 to day 3 cells were terminated and the 
amount of CFDA SE label was analysed by FACS. The 
intensity of CFDA SE was largely reduced from day −2 
until day −1 and again from day −1 to day 0, indicat-
ing that BCECs were highly dividing (Fig.  3). After day 
0 the proliferation seemed to dramatically decrease as 
the BCECs retained approximately the same degree of 
CFDA SE label. This observation corresponded well to 
the microscopic observations of BCECs reaching conflu-
ence at day 0. The curves corresponding to day 1 to day 3 
widened, indicating a more diverse population of BCEC 
division judged from their different CFDA SE label. There 
was a small reduction in the CFDA SE label on day 3 
Page 7 of 14Burkhart et al. Fluids Barriers CNS  (2015) 12:19 
representing a small degree of cell division at this stage. 
The change in the level of CFDA SE label from day 1 to 
day 3 was, however, far from that seen from day −2 to 
day 0.
Transfection of BCECs in primary culture
The model established by culturing the BCECs on the 
inserts was found to exhibit clear signs of BBB integrity 
for approximately 2  days after initiating the co-culture 
between BCECs and astrocytes. Therefore, a 48  h time 
window was available to conduct the transfection experi-
ments. The freshly isolated primary BCECs were seeded 
directly onto inserts and two different stages of BBB 
maturity were defined according to the modified setup 
(Fig. 3). The two stages were: Stage T−1, which is defined 
as the immature state with the BCECs still undergoing 
Fig. 1 Establishment and characterization of in vitro BBB models. a Monoculture consisting of brain capillary endothelial cells (BCECs, yellow), a 
non-contact co-culture of BCECs and astrocytes (green) and a triple culture of BCECs, pericytes (purple) and astrocytes. Astrocytes and pericytes 
were cultured for 21 and 10 days, respectively. The BCECs were cultured for 3 days until 80% confluent. Puromycin was added to the media for 
the first 2 days. On day −1 the pericytes and/or endothelial cells were passaged to each side of the inserts and left to adhere for 24 h. On day 0, 
the inserts used for co- and triple culturing were moved to a plate containing astrocytes, and the BCECs were stimulated with hydrocortisone, 
cAMP and RO. b The cells were identified based on their expression of the tight junction protein ZO1 (BCECs), alpha smooth muscle actin (α-SMA) 
(pericytes) and glial fibrillary acidic protein (GFAP) (astrocytes). The cell nuclei were counterstained with DAPI (blue). Scale bars 10 µm. c The maximal 
TEER values were reached on day 2. Co-cultures (red), and triple cultures (green) displayed TEER values of 299 ± 17 and 331 ± 28 Ω cm2 respec-
tively, while the monoculture (blue) only showed a slight increase in TEER (128 ± 9 Ω cm2). Data are presented as means ± SEM (n = 24). Statistical 
differences were analysed using a 1-way ANOVA with Tukey’s multiple comparisons post hoc test (***p < 0.001). There was no ignificant differ-
ence between co- and triple cultures. d The apparent permeability (Papp) of mannitol in cultured BCECs. Data are calculated based on measure-
ments from 18 inserts with TEER values ranging from 72.4 to 321 Ω cm2. The permeability to mannitol decreases as TEER values increase around 
150 Ω cm2, which can be obtained by co-culturing the BCECs with pericytes and/or astrocytes.
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cell division, and T1, the mature state where the BCECs 
grown in co-culture with astrocytes had established true 
barrier properties. Only stage T1 was co-cultured with 
astrocytes, as transfection at the immature state (T−1) 
was initiated prior to the day of BBB induction (Fig. 4a). 
The BCECs were transfected with a plasmid encoding 
the red fluorescence HcRed1-C1 protein and TEER was 
measured daily. Significantly lower TEER values were 
found at the immature stage (T−1) compared to non-
transfected cells (TCTRL) in the same condition (Fig.  4b, 
left). No significant differences in TEER were found 
between BCECs transfected at the mature state (T1) 
compared to correspondingly grown non-transfected 
cells (Fig. 4b, right). Both of the BCECs preparations had 
TEER values ranging above the critical 130 Ω cm2 at the 
beginning of transfection needed to form a tight barrier 
in the rat (T1: 189 ±  7 Ω  cm2, TCTRL 197 ±  9 Ω  cm2), 
and these TEER values stayed above 130  Ω  cm2 until 
the end of the observation period denoted by 48 h. after 
initiating the transfection (T1: 145  ±  9  Ω  cm2, TCTRL 
145 ± 7 Ω cm2) (Fig. 4b, right).
HcRed1-C1 protein distributed to both cytoplasm 
and the nucleus of BCECs (Figs. 4c, 5a), which indicated 
that the HcRed1-C1 encoding plasmid was success-
fully delivered to the cell nucleus and expressed by the 
BCECs independently of barrier maturity. Pericyte con-
tamination of BCECs could not be excluded, although 
the amount of pericytes was determined to be very low. 
Immunolabeling of transfected cells was performed after 
transfection and this labelling showed that the HcRed1-
C1 positive cells also expressed the tight junction protein 
ZO1, which identifies them as BCECs (Fig. 4c). The cells 
depicted were transfected at day 1 (T1); however, ZO1 
and HcRed1-C1 positive cells were found in both trans-
fection setups (data not shown).
Correlation between barrier properties and transfection 
efficiency
The HcRed1-C1 gene expression by BCECs was evalu-
ated by RT-qPCR analysis and confirmed gene expression 
in the two culture conditions (Fig.  5b). The expression 
after T−1 and T1 transfection was 3.7 ± 0.8 and 3.7 ± 0.6, 
respectively. HcRed1-C1 gene expression was not found 
in non-transfected cells (TCTRL). The expression of the 
claudin-5 gene was, additionally, included in this analysis 
to simultaneously evaluate the endothelial origin of the 
transfected cells and the degree of tight junction forma-
tion. Claudin-5 was present in all three situations. No sig-
nificant differences were found in the expression pattern 
of claudin-5 among the three groups, although there was 
a tendency towards claudin-5 being lowest in the imma-
ture state (T−1), which correlated with the lower TEER 
value.
The transfection efficacy was furthermore analysed by 
flow cytometry (Fig.  5c). The BCECs were transfected 
with the red fluorescent HcRed1-C1 protein at the two 
different stages of barrier maturity for 48  h. Unlabelled 
cells were used to assess the auto fluorescence and to 
ensure that less than 1% of the HcRed1-C1 positive cells 
were false positive. A transfection efficiency of approxi-
mately 4% was found both in the immature dividing state 
(T−1) and in the mature state (T1).
Fig. 2 Gene expression analysis of the hall mark proteins related 
to brain capillary endothelial cells (BCECs). RNA was obtained from 
BCECs grown in mono- (blue), co- (red) and triple- (green) culture 
conditions at day 1 and analysed for the expression of BCECs hallmark 
genes (claudin-5, occludin, PECAM-1, ABCG2, ABCB1 and Transfer-
rin receptor 1 (TfR1)). The relative gene expression among the three 
culture conditions was statistically analysed using 1-way ANOVA with 
Tukey’s multiple comparisons post hoc test. Data are presented as 
sample means ± SEM (n = 8). p < 0.05, **p < 0.01, ***p < 0.001.
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Discussion
Establishment of the in vitro BBB model
BCECs were cultured in monolayer, and the effects of co-
culturing the BCECs with astrocytes and pericytes were 
analysed based on TEER values, and gene expression pro-
files using a variety of BBB specific proteins. The passive 
permeability was analysed in relation to TEER and clearly 
demonstrated that TEER values around 150 Ω cm2 were 
sufficient to obtain low permeability, as the co-cultures 
reached TEER values near 300 Ω cm2 that coincided with 
low passive permeability. This corresponds very well to 
the data presented by Gaillard and de Boer, where they 
found that as TEER values above 130 Ω  cm2, were suf-
ficient to establish a tight in vitro BBB model using pri-
mary cells isolated from rat brains [36]. As the TEER 
values in monocultures of the BCECs never exceeded 
130  Ω  cm2, this culture did not reach the demands for 
a tight in  vitro BBB model. Astrocytes had the highest 
impact on BCECs as only minor, non-significant effects 
was seen when culturing BCECs in presence of both 
astrocytes and pericytes with regard to TEER values.
Astrocyte-endothelial interactions are important for 
establishment and regulation of BBB properties of BCECs 
in vitro [1, 5, 37]. This mimicking recapitulated many fea-
tures of the BBB in vivo; a dramatic increase in TEER due 
to increased expression of tight junction proteins [15, 19, 
32], lowering of passive permeability [19] and up-regula-
tion of important nutrient transporters [38, 39]. The fact 
that the addition of astrocytes to the BCECs to develop 
the co-culture raised the TEER value substantially shows 
that astrocytes play a pivotal role for induction of BBB 
properties in  vitro. Pericytes also induce the BBB phe-
notype in BCECs cultured in  vitro [2, 16, 19], although 
the data of the present study did not find evidence that 
pericytes, when added to astrocytes formed significantly 
improved BBB characteristics of BCECs.
Fig. 3 Analysis of the cell proliferation of brain capillary endothelial cells (BCECs) from barrier culture days −2 to 3 using a 5-and 6-carboxylfluo-
rescein diacetate succinidyl ester (CFDA SE) assay. BCECs were isolated on day −3 and seeded directly onto inserts. 1 µM CFDA SE was added to 
the cells at day −2. After 30 min of incubation all the cells were labelled with CFDA SE and the first group were terminated (T−2) (red). Every day for 
5 days one group (T−1 to T3) (blue, orange, green, black and purple, respectively) were terminated. The BCECs were microscopically visualised to be 
confluent on day 0, and subsequently co-cultured with astrocytes and stimulated with hydrocortisone, cAMP and RO-201724. The cells were exam-
ined on BD FACS canto™ and analysed with the FlowJo v10 software. The cells were gated using forward and side scatter to eliminate cell debris. 
Unlabelled BCECs (purple) were used as a negative control.
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That BCECs did not statistically increase TEER under 
influence of pericytes could reflect the differential state 
of the pericytes. The expression of α-SMA by pericytes 
affect the BBB properties of BCECs, as α-SMA posi-
tive pericytes are unable to increase TEER, whereas 
the reverse applies to α-SMA negative pericytes [40]. 
When grown in monoculture pericytes differentiate 
into α-SMA negative state when exposed to bFGF but 
becomes α-SMA expressing in the presence of trans-
forming growth factor β (TGFβ) [40]. When culturing 
the pericytes together with BCECs and astrocytes in tri-
ple culture, they invariably get exposed to both bFGF and 
TGFβ secreted by astrocytes [5, 41–43]. Moreover, bFGF 
was added to the cell media used for BCECs. Possibly, the 
influence of TGFβ secreted by astrocytes drives pericytes 
towards their α-SMA expressing state that subsequently 
leads to less BBB inductive functions. The differentia-
tion state of the pericytes was, therefore, difficult to con-
trol and might have resulted in different differentiation 
of pericytes, resulting in large variability in the TEER 
values.
TEER values of the co and triple cultures increased 
until day 2 after which they started to decrease. Hence, 
TEER values remained high above 130 Ω cm2 for at least 
48 h. after stimulating the cells to increase their expres-
sion of tight junction proteins. A single study reported 
Fig. 4 The effect of transfection on the integrity of the brain capillary endothelial cells (BCECs). a The experimental design used for in vitro transfec-
tion of BCECs. BCECs (yellow) were isolated on day -3, seeded directly onto the inserts. Barrier properties were induced by co-culturing with astro-
cytes (green) in the presence of hydrocortisone, cAMP and RO-201724. BCECs were transfected at two different stages of barrier maturity: T−1, an 
immature state, defined by dividing BCECs without barrier properties, and T1, a mature state defined as the BCECs being confluent and having bar-
rier properties. b The integrity of the transfected BCECs (T−1 and T1) (black) was monitored daily by measurements of TEER and compared to non-
transfected cells (TCTRL) (grey). Left non-confluent BCECs transfected on day −1 (T−1). No attempts were made to increase tight junction formation. 
Right on experimental day 1, barrier properties were present (TEER above 150 Ω cm2) in both transfected and control BCECs and lasted for at least 
2 days. Significant differences among the two states and their respective controls were analysed using 1-way ANOVA with Tukey’s multiple com-
parisons post hoc test (***p < 0.001). No significant difference was found between T1 and TCTRL. Data are presented as means ± SEM (n = 34–44). c 
To investigate the origin of the HcRed1-C1 positive cells, an immunocytochemical analysis was performed for the tight junction protein ZO1. The 
cells illustrated were transfected at day 1 (T1) and examined 48 h after transfection. The illustrations depict a BCEC containing both the HcRed1-C1 
protein and the ZO1 protein (green). Nuclei are counterstained with DAPI (blue). Scale bar 10 µm.
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that TEER values remained high for more than 5  days 
in non-transfected conditions [2], while another group 
report that the TEER values of non-transfected BCECs 
decrease after day 3 [44]. We have a suspicion that dif-
ferences in maintaining the barriers between different 
research groups could derive from variations in the han-
dling of the cell cultures, e.g. the use of the chopstick for 
measuring TEER demands the removal of the cells from 
the incubator multiple times. This invariably affects the 
buffer capacity of the media [33], which consequently 
may loosen the astrocytic cell layer from the culture 
wells. Supporting our notion, when non-transfected 
BCECs were co-cultured with astrocytes and left undis-
turbed in the incubator for 3  days, the endothelial cells 
Fig. 5 The transfection efficiency of brain capillary endothelial cells (BCECs) at different stages of barrier maturity. a Expression of HcRed1-C1 fluo-
rescent protein as seen in BCECs 48 h after transfection. HcRed1-C1 positive cells were expressed at both stages of barrier maturity. The HcRed1-C1 
protein distributed to both the cell nucleus and cytoplasm. Scale bar 10 µm. b The relative gene expression of HcRed1-C1 was investigated with 
RT-qPCR at the two different states of barrier maturity: T−1 (blue) and T1 (green). Non-transfected cells (TCTRL) (purple) showed no HcRed1-C1 gene 
expression. The gene expression of claudin-5 was included to evaluate the origin of the transfected cells and to measure the degree of tight junc-
tion formation at the various stages of barrier maturity. The relative gene expression among the three culture stages was statistically analysed using 
1-way ANOVA with Tukey’s multiple comparisons post hoc test (**p < 0.01). Data are presented as sample means ± SEM (n = 6–8). No significant 
differences were found in the expression pattern of claudin-5 among the three groups. c The transfection efficacy of BCECs was additionally 
assessed by flow cytometry. A transfection efficacy of about 4% was found in both the immature highly diving stage (T−1) and in the mature non-
dividing stage (T1). Results were analysed using the FlowJo V10 software. The cells were gated using forward and side scatter to eliminate cell debris. 
Additionally, the cells were corrected for auto fluorescence using unlabelled BCECs (purple) to ensure that less than 1% of the HcRed1-C1 positive 
cells were false positive. Scale bar 10 µm.
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maintained their TEER value around 180 Ω  cm2, which 
clearly suggests that handling the co-cultures can nega-
tively affect the barrier integrity.
Transfection of BCECs in primary culture
For transfection purposes, the BCECs were grown 
directly on filters, which ensured that only BCECs would 
take up the transfections agent but also that the cells 
could undoubtedly be characterised as primary cells (P0). 
However, this led to a lower, albeit still clearly accepta-
ble, high TEER value indicative of good integrative BBB 
properties. TEER values were generally lower when the 
BCECs were seeded directly onto the filters, compared to 
when they were passaged on the filters 3 days after isola-
tion. We believe this could relate to the presence of cell 
debris and capillary fragments on the filters, which were 
otherwise removed during the passaging step. However, 
TEER invariably remained above 130  Ω  cm2 indicating 
that the BBB integrity was clearly maintained during the 
transfection situation. Based on co-culture conditions, 
we introduced genetic material into BCECs at different 
states of barrier maturity, which enabled us to moni-
tor correlations between cell division, barrier maturity 
and transfection efficiency. Cells undergoing mitosis are 
more prone to gene therapy than non-dividing cells [45]. 
However, the majority of BCECs are post-mitotic in vivo 
[30], which complicates the introduction of new genetic 
material [46]. This problem can be overcome using a 
viral vector with mechanisms for nuclear internalisa-
tion in non-dividing cells [46]. Despite high efficiency 
for cellular insertion of genetic material including cells of 
the CNS [47–50]; viral vectors may, however, also exert 
unwanted effects [51]. We therefore investigated trans-
fection efficiency of BCECs taking a non-viral approach 
using Turbofect, a cationic polymer that forms stable and 
positively charged complexes with DNA. According to 
the manufacturer, Turbofect has low cytotoxicity, is inde-
pendent of serum-free conditions, and considered suit-
able for transfection of primary cells.
No difference was found in the percentage of trans-
fected cells, which in both cases were around 4%. Inter-
estingly, BCECs grown in the mature state of the BBB 
also took up HcRed1-C1 gene material and transcribed 
it without influencing the tightness of the cell layer. This 
observation suggests that transfection may be independ-
ent of cell division and that transfection of non-dividing 
cells with barrier properties is as effective as transfection 
of dividing cells without barrier properties.
Previous transfection studies on BCECs were per-
formed in monocultures without polarised conditions 
[23, 26, 52, 53]. We performed transfection under polar-
ised conditions by adding genetic material to luminal 
side. Theoretically, this material could pass though tight 
junction complexes and enter BCECs via the abluminal 
side. This option was, however, not likely when consid-
ering the size of the plasmid-Turbofect complex and the 
high expression of tight junction proteins. Supporting 
this notion, we found no expression by astrocytes present 
on the abluminal side of BCECs.
Cytoplasmic delivery is one of several obstacles in the 
design of drug carriers. The ultimate challenge could be 
the entry of genetic material into the nuclear envelope. 
Molecules smaller than approximately 40  kDa are able 
to diffuse passively into the nucleus via nuclear pore 
complexes, while macromolecules larger than 60  kDa 
require a nuclear localisation sequence. The size of plas-
mid DNA makes it unlikely that nuclear entry occurs 
through passive diffusion [54]. The transfection efficacy 
has been reported to be higher in mitotic cells than 
in quiescent counterparts [27, 45, 46], which has led 
to the idea that plasmid DNA enters the nucleus dur-
ing disassembly of the nuclear envelope during mitotic 
cell division [45, 54]. Studies investigating the correla-
tion between mitotic activity and transfection efficacy 
revealed that transfection was probable even when cells 
were arrested in the G1phase [27, 45, 46], which indi-
cates that plasmid DNA might permeate the nuclear 
pore complexes by a mechanism that resembles the 
active transport of polypeptides larger than 60 kDa [29, 
54]. Therefore, transfection of BCECs when they enter 
their quiescent stage may relate to active transport of 
plasmid DNA though the nuclear pore complex not 
directly related to cell division.
Many therapeutic polypeptides are acknowledged for 
their neuroprotective effects [55, 56]. Prospects of using 
BCECs as protein factories to enable transport of neuro-
protective polypeptides into the brain without a need to 
pass the BBB are substantial [22]. The present study is the 
first to demonstrate non-viral gene therapy to BCECs in 
cultures with defined BBB properties. The present study 
revealed transfection efficacies around 4%. It is however 
questionable whether this percentage of transfected cells 
would be enough to see any therapeutic effects in  vivo. 
In comparison transfection of HeLa cells with identical 
plasmid and transfection agent results in a transfection 
efficiency of 46% (unpublished results). We are there-
fore currently testing other non-viral gene carriers in 
order to increase the transfection efficiency of the non-
mitotic BCECs. Further studies also need to examine 
the potential of secretion from BCECs transfected with 
DNA encoding neuroprotective proteins like recombi-
nant erythropoietin and brain derived neurotrophic fac-
tor (BDNF). Nonetheless, the current study is the first 
crucial step in the evaluation of the use of non-viral gene 
therapy to non-mitotic BCECs with defined BBB proper-
ties as a potent future drug delivery strategy to the CNS.
Page 13 of 14Burkhart et al. Fluids Barriers CNS  (2015) 12:19 
Conclusions
In conclusion, non-viral transfection of polarised BCECs 
with defined BBB properties enabled gene expression even 
in conditions with low mitotic activity, hence simulating 
the in vivo condition. Transfection did not disrupt the BBB 
integrity judged from the conserved expression of tight 
junction proteins. Moreover, transfection was independent 
of cell division, and as effective as transfection of dividing 
cells without barrier properties. The data clearly indicate 
that non-viral gene therapy of BCECs is possible in culture 
conditions with an intact BBB. The data also suggest that 
genetically modification of BCECs in vivo might be a feasi-
ble drug delivery strategy in the future.
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